To examine the antiproliferative and pro-inflammatory effects of two RSK inhibitors, we treated a panel of nine human melanoma cell lines with the unselective BI-D1870 (Edgar et al, 2014) and the selective LJH685 (Aronchik et al, 2014). This evidence concerns the gene RPS6KA1 and melanoma.